(Source: Business Wire)ArthroCare Corp. (NASDAQ: ARTC) announced today that, as expected, it received an additional NASDAQ Staff Determination Letter on November 12, 2008 in connection with the Company's inability to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2008 with the Securities and Exchange Commission (the "SEC"). The Additional Staff Determination letter states that the Company is therefore not in compliance with NASDAQ Marketplace Rule 4310(c)(14), and that this issue may serve as an additional basis for the NASDAQ Listing Qualifications Panel (the "Panel") to delist its common stock from NASDAQ.

As previously disclosed on August 19, 2008, the Company received a similar NASDAQ Staff Determination letter on August 13, 2008 in connection with the Company's inability to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2008 with the SEC. The Company appealed that Staff Determination and attended a hearing before the Panel this fall during which the Company requested that the Panel grant additional time to regain compliance with NASDAQ's filing requirement. Pending a decision by the Panel, the Company's common stock will remain listed on The NASDAQ Global Select Market. There can be no assurance that the Panel will grant the Company's request for continued listing.

ABOUT ARTHROCARE

Founded in 1993, ArthroCare Corp. (www.arthrocare.com) is a highly innovative, multi-business medical device company that develops, manufactures and markets minimally invasive surgical products. With these products, ArthroCare targets a multi-billion dollar market opportunity across several medical specialties, significantly improving existing surgical procedures and enabling new, minimally invasive procedures. Many of ArthroCare's products are based on its patented Coblation technology, which uses low-temperature radiofrequency energy to gently and precisely dissolve rather than burn soft tissue ” minimizing damage to healthy tissue. Used in more than four million surgeries worldwide, Coblation-based devices have been developed and marketed for sports medicine; spine/neurologic; ear, nose and throat (ENT); cosmetic; urologic and gynecologic procedures. ArthroCare also has added a number of novel technologies to its portfolio, including Opus Medical sports medicine, Parallax spine and Applied Therapeutics ENT products, to complement Coblation within key indications.